Compare GEO & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | DAWN |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 1996 | 2021 |
| Metric | GEO | DAWN |
|---|---|---|
| Price | $18.60 | $21.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $39.67 | $24.43 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 727.27 | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $2,263,420,000.00 | $158,182,000.00 |
| Revenue This Year | $13.74 | $55.03 |
| Revenue Next Year | $9.99 | $28.12 |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | 3.85 | ★ 20.60 |
| 52 Week Low | $12.51 | $5.64 |
| 52 Week High | $32.09 | $21.50 |
| Indicator | GEO | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 65.09 | 79.77 |
| Support Level | $16.06 | $10.30 |
| Resistance Level | $18.72 | $21.50 |
| Average True Range (ATR) | 0.74 | 0.03 |
| MACD | 0.03 | -0.32 |
| Stochastic Oscillator | 92.84 | 77.27 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services. The company operates in U.S, Australia and South Africa.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.